Why Regado Biosciences Inc. Stock Imploded

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Regado Biosciences (NASDAQ: RGDO  ) , a clinical-stage biopharmaceutical company focused on developing drugs used to thwart thrombotic events in acute and non-acute cardiovascular indications, imploded and fell as much as 58% after it announced the initiation of an unplanned data safety monitoring board review of REG1 (also known as Revolixys Kit), its lead investigational antithrombotic drug system.

So what: According yesterday's late-night press release, patient enrollment in Regado's REGULATE-PCI trial has been halted until the Data Safety Monitoring Board completes a review which is expected within the next eight weeks. As noted, the DSMB plans to conduct "a full analysis of safety and treatment benefit-risk ratio of all patients enrolled to date (3,234) with a focus on serious adverse events related to allergic reactions."

Now what: There's obviously a lot of promise behind REG1 as it targets a wide audience of acute coronary syndrome patients and could give physicians the ability to up- and down-regulate anticoagulation properties to avoid potential bleeding incidents in patients while also protecting them from potentially deadly blood clots.

However, beyond REG1 Regado's pipeline is fairly thin. It has REG2, a venous thrombosis-fighting therapy that just began phase 1 studies and REG3, a preclinical anti-platelet candidate. Therefore, if there are concerns about REG1's safety this early on in its extensive phase 3 study then Regado's valuation, should REG1 not succeed or be proven too dangerous relative to its benefits profile, may likely take a major hit – perhaps even bigger than today's drop. With no partner on this project, and now plenty of questions raised regarding REG1's safety, I believe you have all the makings of a stock you should keep your distance from.

Regado may offer plenty of potential, but this revolutionary product is likely to leave it in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 3017764, ~/Articles/ArticleHandler.aspx, 7/23/2014 12:46:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement